Pharmaceutical News

RSS

Study finds nutritional risks in users of GLP-1 drugs

Adults with overweight or obesity taking the new generation of weight loss drugs semaglutide and tirzepatide tend to eat significantly less, leaving them vulnerable to nutritional deficiencies, according to one of the first real-world studies to examine dietary behavior in people using glucagon-like peptide-1 receptor agonists and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) dual agonists RAs (collectively referred to as GLP-1 RAs) with the help of an AI-powered nutritional tracking app.

9 Apr 2026

FTC drug divestiture policy may reduce competition, study finds

Last month, Novartis completed its $11 billion acquisition of Avidity Biosciences-the latest in a string of major pharmaceutical mergers including Merck's acquisition of Verona Pharma and GSK's acquisition of RAPT Therapeutics.

9 Apr 2026

Sponge and sea slug partnership yields a new anticancer molecule with drug design promise

Researchers identified jorumycidine, a new hexacyclic marine alkaloid from the nudibranch Jorunna funebris and its dietary sponge, Haliclona sp., and demonstrated that it exhibits potent nanomolar cytotoxicity against multiple myeloma cells. They also proposed a new biosynthetic route involving cross-species metabolic interplay and an unusual oxazolidine ring that may help stabilize a pharmacologically important scaffold.

8 Apr 2026

Insilico Medicine nominates AI-driven drug candidate for cancer, Cushing's syndrome and obesity

The NR3C1 (nuclear receptor subfamily 3 group C member 1) gene encodes the glucocorticoid receptor (GR), a nuclear receptor vital for maintaining physiological homeostasis, and inhibition of NR3C1 could increase the sensitivity of cancer cells to standard chemotherapy, particularly in ovarian cancer.

8 Apr 2026

Study finds genetic basis for GLP-1 weight loss efficacy and side effects

23andMe Research Institute, a nonprofit medical research organization, announced the publication of a study that identifies genetic predictors for GLP-1 weight loss efficacy and side effects.

8 Apr 2026

Study identifies a common brain activity pattern across psychedelics

Scientists have demonstrated, for the first time, that several psychedelic drugs – including psilocybin, LSD, mescaline, DMT and ayahuasca – produce a common pattern of brain activity despite their distinct chemistries.

8 Apr 2026

Long-term study links common IBS medications to mortality risk

A large, long-term study led by Cedars-Sinai Health Sciences University investigators suggests that some medications commonly prescribed to treat irritable bowel syndrome (IBS)-including antidepressants-may be associated with a small but measurable increase in the risk of death.

8 Apr 2026

Metformin boosts an exercise-linked metabolite and may help control weight in prostate cancer patients

Metformin raised the exercise-linked metabolite Lac-Phe in prostate cancer patients across disease stages and treatment settings, while Lac-Phe itself did not predict anticancer response. Patients in the BIMET-1 metformin arm also showed better weight management during anti-androgen therapy, highlighting a possible metabolic benefit relevant to prostate cancer care.

7 Apr 2026

AI helps researchers find antimicrobial peptides in Earth’s harshest habitats

Researchers built the Extreme Environment Microbiome Catalog from 78,213 genomes across global extreme habitats, revealing major taxonomic and biosynthetic novelty, including 32,715 representative species, nearly 4 billion non-redundant genes, and 163,693 biosynthetic gene clusters. They then used protein language models to identify 3,032 candidate non-toxic antimicrobial peptides, with 84 of 100 synthesized peptides showing antibacterial activity and low cytotoxicity in the 50 tested in mammalian cells.

6 Apr 2026

Flu vaccination may cut heart attack and stroke risk after infection

In Danish adults aged 40 years or older, laboratory-confirmed influenza was linked to a sharp short-term rise in first-time heart attack and stroke risk, especially in the first 7 days after infection. Prior same-season influenza vaccination was associated with about half the excess cardiovascular risk among infected individuals, suggesting possible protection even in breakthrough cases.

6 Apr 2026

Metformin mimics exercise-related metabolic effects in prostate cancer patients

A new study has found that metformin, a widely prescribed diabetes drug, may mimic one of exercise's core biological effects in men with prostate cancer, raising levels of a molecule tied to energy balance and weight control even when patients are inactive.

6 Apr 2026

Semaglutide for weight loss was linked to a sharp drop in alcohol use in this case report

A 2026 case report describes a 34-year-old man with obesity and alcohol use disorder whose semaglutide treatment for weight loss was associated with a marked drop in drinking over 10 months, with his AUDIT score falling from 27 to 7 and alcohol use dropping from about 15 drinks per week to half a beer per month. The authors frame this as a promising but preliminary finding that adds to growing evidence on GLP-1 drugs and alcohol use, while also stressing that this was a single case and that better AUD screening in family medicine remains important.

2 Apr 2026

Advances in nanomedicine improve anthelmintic drug delivery and effectiveness

Announcing a new article publication in BIO Integration. According to World Health Organization (WHO) reports, parasitic infections substantially affect the world's population and are responsible for more than 16 million annual deaths in developing countries.

2 Apr 2026

High-dose flu shots inked to lower Alzheimer's dementia risk in older adults

A large US claims-based study found that adults aged 65 and older who received a high-dose flu vaccine had a lower observed risk of Alzheimer dementia than those who received a standard-dose vaccine, with the association lasting up to 25 months in per-protocol analyses and 28 months in intention-to-treat analyses. The signal appeared stronger and more sustained in women, though the authors stress that the findings are observational and need confirmation in longer prospective studies.

2 Apr 2026

Highly potent opioid shows potential as therapy for pain and opioid use disorder

Researchers at the National Institutes of Health (NIH) have identified a novel, highly potent opioid that shows potential as a therapy for both pain and opioid use disorder.

1 Apr 2026

FDA approves first gene therapy for rare pediatric immune disorder

Dr. Donald Kohn has been developing gene therapies for rare pediatric immune disorders for over 30 years.

27 Mar 2026

Guselkumab shows minor added benefit for specific Crohn's disease patients

The human monoclonal antibody guselkumab has been approved for certain adults with moderately to severely active ulcerative colitis since April 2025.

27 Mar 2026

GLP-1 medications show mixed effects on body contouring outcomes

For patients undergoing body contouring surgery to remove excess abdominal skin after massive weight loss, use of GLP-1 weight-loss medications may have mixed effects on complication risks, suggests a study in the April issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons.

26 Mar 2026

Taking a GLP-1? Doctors say not to forget about movement and mental health

Severe ankle pain drove Jelon Smart to start taking a weight loss injection a year and a half ago.

26 Mar 2026

Blood pressure drug boosts effectiveness of cancer therapy

In a new Dartmouth Cancer Center (DCC) study led by clinical researcher Tyler J. Curiel, MD, MPH, FACP, investigators found that the FDA-approved blood pressure drug telmisartan can significantly enhance the cancer-killing activity of the targeted therapy olaparib, potentially expanding its use to many more patients.

25 Mar 2026